Abstracts Archive - Page 227 of 2607 - ACR Meeting Abstracts

Abstract Number: 2587 • ACR Convergence 2024
A Proprietary AI Rule Engine Assisted by an OpenAI-based ML Model Can Speed up and Better Inform the Prior Authorization Process for Rheumatology Investigations and Medications
Tanishka Agrawal¹, Sumanth Raman², J. Arun³ and HUMEIRA BADSHA⁴, ¹Dubai International Academy, Dubai, Dubai, United Arab Emirates, ²Algorithm Health, Dubai, Dubai, United Arab Emirates, ³Algorithm Health, Dubai, United Arab Emirates, ⁴HBMC, Dubai, United Arab Emirates
Background/Purpose: Patients with chronic autoimmune conditions often need expensive treatments which require prior authorizations by insurance companies. However, significant delays in these processes leave patients…
Abstract Number: 0641 • ACR Convergence 2024
Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients
Katherine Chakrabarti¹, Apurba Chakrabarti², Emily Lewis² and William McCune³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Hospital, Ann Arbor, MI, ³U Michigan, Ann Arbor, MI
Background/Purpose: Traditionally, a coronary artery calcium (CAC) score of zero is associated with low rates (0.1-0.2% annualized risk) of major adverse cardiovascular outcomes (MACE). While…
Abstract Number: 2567 • ACR Convergence 2024
Gene Expression in Osteonecrosis of the Femoral Head: A Region-matched RNA-sequencing Study
Lucy Eunju Lee¹, Seung Hwan Lee², Miri Kim², Jieun Kim², Joo Sung Shim², Eun Gyel Shin², Tae Sung Lee², Hyuck Min Kwon², Young Han Lee², Hun-Mu Yang², Kwan Kyu Park² and Jason Jungsik Song², ¹Yonsei University, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Osteonecrosis of the femoral head (ONFH) is linked to diverse risk factors like glucocorticoid use and excessive alcohol consumption. Various cells may influence bone…
Abstract Number: 2594 • ACR Convergence 2024
A Novel Therapeutically Active CSF-1R Agonist Promotes Tissue Macrophages Inflammation Resolution and Induces Tissue Repair Pathways
Saul Kivimae¹, Sandip Mukherjee², Phi Quach³, Rhoneil Pena⁴, Olga Zemska³, Michal Olszewski⁵, Jicai Huang³, Michael Labson⁶, Donald Walker¹, Mekhala Maiti⁷, Chakrapani Tripathi⁸, Thomas Chang³, Suresh Adapala⁹, Damon Hamel³, Katherine Brendza³, Takahiro Miyazaki³ and Jonathan Zalevsky¹, ¹Nektar Therapeutics, San Francisco, CA, ²Nurix Therapeutics, San Francisco, ³Nektar Therapeutics, San Francisco, ⁴Sutro Biopharma, South San Francisco, ⁵Vaxcyte, San Francisco, ⁶Guardant Health, Palo Alto, ⁷Alumis, Inc, South San Francisco, ⁸Theragent Inc, Arcadia, CA, ⁹Inotiv, Rockville, MD
Background/Purpose: Current standard of care chronic inflammatory disease therapies are designed to suppress inflammation and are not optimized for inflammation resolution and restoration of tissue…
Abstract Number: 0649 • ACR Convergence 2024
Urinary Acetylated Albumin as a Biomarker of Nephritis in Patients with Systemic Lupus Erythematosus
Yeo-Jin Lee¹, Eun-Ju Lee², Minji Kim³, Mi-Ra Cho⁴, Soo Min Ahn³, Seokchan Hong⁴, Ji Seon Oh⁴, Chang-Keun Lee⁴, Bin Yoo⁴ and Yong-Gil Kim³, ¹Asan medical center, Seoul, South Korea, ²Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea, ³Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea, ⁴Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multi-organ systems, particularly the kidneys. Urine is an ideal source of SLE biomarkers…
Abstract Number: 0366 • ACR Convergence 2024
Factors Associated with Participation in Rheumatology Clinical Trials: A UK-based Study
Koushan Kouranloo¹ and Chris Wincup², ¹Internal Medicine Resident., London, United Kingdom, ²King's College Hospital, London, United Kingdom
Background/Purpose: Clinicians are encouraged to consider patient preferences for offering face-to-face vs virtual consultations. This adaptability is particularly important to rheumatologists caring for patients with…
Abstract Number: 0390 • ACR Convergence 2024
Treatment Effectiveness Following Switching from Initial TNF Inhibitor in Juvenile Idiopathic Arthritis
Mei-Sing Ong¹, Sarah Ringold², Melissa Mannion³, Marc Natter⁴ and Yukiko Kimura⁵, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ²Washington University, Seattle, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Boston Children's Hospital, Boston, MA, ⁵Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Although the increasing availability of biologic therapies has significantly improved outcomes for patients with JIA, a substantial proportion of patients require switching from the…
Abstract Number: 0367 • ACR Convergence 2024
Opinions from Rheumatoid Arthritis Patients and Providers on Discontinuing Methotrexate in Stable Disease
Peri Newman¹, Sharon Banks¹, Rayford June², Erik Lehman³, Glennys Smith⁴, Vandana Rai⁴, Nicole Wilson⁴, Nancy Olsen⁵ and Tarun Sharma⁴, ¹Penn State Health, Hershey, PA, ²Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA, ³Penn State College of Medicine, Hershey, PA, ⁴Allegheny Health Network, Pittsburgh, PA, ⁵Penn State University/Milton S Hershey, Hershey, PA
Background/Purpose: The 2021 American College of Rheumatology guidelines for treatment of rheumatoid arthritis (RA) conditionally recommend a gradual discontinuation of methotrexate (MTX) over biologic discontinuation.…
Abstract Number: 0384 • ACR Convergence 2024
Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study
Corey J. Bishop¹, Edwin Lam², Sophia G. Liva³, Jocelyn H. Leu², Amy S. Paller⁴, Lucia Z. Diaz⁵, Laura Wine Lee⁶, Cory Rubin⁷, Ruy Carrasco⁸, Lisa Imundo⁹, Azadeh Majlessi¹⁰, Katherine Berezny¹, Kathleen G. Lomax¹, Valerie Smith¹, Renping Zhang¹ and hermine brunner¹¹, ¹Janssen Research & Development, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, ³Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ⁴Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁵Dell Children’s Medical Center; Dell Medical School at the University of Texas at Austin, Austin, TX, ⁶Medical University of South Carolina, Charleston, SC, ⁷Michigan Dermatology Institute, Waterford, MI, ⁸Pediatric Rheumatology Consultants of Austin, Austin, TX, ⁹Columbia University Medical Center, New York, NY, ¹⁰Newport Huntington Medical Group, Huntington Beach, CA, ¹¹Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Ustekinumab (UST), an interleukin‑12/23p40 antagonist, is currently approved for juvenile psoriatic arthritis (jPsA) solely in the United States (US). Although a phase 3 study…
Abstract Number: 0373 • ACR Convergence 2024
Enhancing Lupus Patient Education and Support at Kings County Hospital
Dmytro Gatsak¹, Jayashree Gandhi¹, Aleksander Feoktistov², Eugeniya Golub³ and Michael Trevisonno⁴, ¹Kings County Hospital/ SUNY Downstate Medical Center, Brooklyn, NY, ²Kings County Hospital Center/ H+H NYC, Brooklyn, NY, ³Kings County Hospital/ SUNY Downstate Medical Center, Staten Island, NY, ⁴State University of New York Downstate Medical Center, Brooklyn, NY
Background/Purpose: Kings County Hospital, located in Brooklyn, New York, sees an estimated 243 patients with Systemic Lupus Erythematosus (SLE) annually. The patient demographic is predominantly…
Abstract Number: 0377 • ACR Convergence 2024
Improving Self-Management Support in Patients with Juvenile Idiopathic Arthritis
Julia Harris¹, Leslie Favier², Emily Fox³, Michael Holland³, Cara Hoffart⁴, Maria Ibarra³, Jordan Jones⁴, Susan Parish², Kara Remick-Erickson² and Ashley Cooper⁴, ¹Children's Mercy Kansas City, Overland Park, KS, ²Children's Mercy Kansas City, Kansas City, ³Children's Mercy Hospital, Kansas City, MO, ⁴Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Self-management support (SMS) is one of the key elements of the Chronic Care Model as it is an important aspect of the care for…
Abstract Number: 0378 • ACR Convergence 2024
Disparate Disease Activity Outcomes Associated with Demographic Variables in Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
Julia Harris¹, Catherine Bingham², Sheetal Vora³, Cagri Yildirim-Toruner⁴, Kerry Ferraro⁵, Erik Friedrichsen⁶, Michelle Batthish⁷, Jon Burnham⁸, Danielle Fair⁹, Suhas Ganguli¹⁰, Mileka Gilbert¹¹, Beth Gottlieb¹², Tzielan Lee¹³, Daniel Lovell¹⁴, Melissa Mannion¹⁵, Edward Oberle¹⁶, Nancy Pan¹⁷, Linda Ray¹⁸, Michael Shishov¹⁹, Mary Toth²⁰ and Esi Morgan²¹, ¹Children's Mercy Kansas City, Overland Park, KS, ²Penn State Children’s Hospital, Hershey, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁵JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁶Seattle Children's Hospital, Seattle, ⁷McMaster Children's Hospital, Hamilton, ON, Canada, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ¹⁰Hackensack University Medical Center, Hackensack, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Cohen Children's Medical Center, Lake Success, NY, ¹³Stanford University School of Medicine, Palo Alto, CA, ¹⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵University of Alabama at Birmingham, Birmingham, AL, ¹⁶Nationwide Children's Hospital, Columbus, OH, ¹⁷Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ¹⁸University of Mississippi Medical Center, Jackson, MS, ¹⁹Phoenix Children's Hospital, Phoenix, AZ, ²⁰Nemours Foundation, Orlando, FL, ²¹Seattle Children's Hospital, Seattle, WA
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a North American learning health network focused on improving outcomes in patients with juvenile…
Abstract Number: 0371 • ACR Convergence 2024
This Is Caring: Enhancing Patient Education Materials for Individuals with Morphea Through Qualitative Inquiry
Jennifer Foster¹, Robin Higashi², Priya Sarlashkar¹ and Heidi Jacobe¹, ¹The University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX, ²2UT Southwestern Medical Center, Peter O’Donnell Jr School of Public Health, Dallas, TX
Background/Purpose: Patient education materials (PEMs) are essential for conveying disease and treatment information, empowering patients to actively participate in their care. However, PEMs for rare…
Abstract Number: 0369 • ACR Convergence 2024
Can Treatment Expectations or Treatment Itself in Patients with Arthralgia Suspicious for Progression to Rheumatoid Arthritis Improve Illness Perceptions?
Simonetta van Griethuysen¹, Quirine Dumoulin² and Annette van der Helm-van Mil³, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Negative Illness perceptions (IPs) are associated with poorer disease outcomes in rheumatoid arthritis (RA). Unfortunately, IPs are generally fixed in established RA. We hypothesized…
Abstract Number: 0379 • ACR Convergence 2024
Effectiveness and Safety of Baricitinib for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis in Children
Athimalaipet Ramanan¹, Catherine Guly², Gabriele Simonini³, Stuart Keller⁴, Priyanka Sen⁴, Thorsten Holzkaemper⁴ and PIERRE QUARTIER⁵, ¹Bristol Royal Hosp for Children, Bristol, United Kingdom, ²University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, ³Meyer Children’s Hospital IRCCS; University of Florence, Florence, Toscana, Italy, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France
Background/Purpose: Baricitinib could target multiple cytokine pathways associated with juvenile idiopathic arthritis associated uveitis (JIA-U) and antinuclear antibody (ANA)-positive uveitis, providing a novel therapeutic approach.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].